Advances in Transcription Factor Delivery for Cancer Gene Therapy

A new research report from the Inha University College of Medicine in South Korea discusses the recent advancements in delivery systems for transcription factors (TFs), which have opened new therapeutic opportunities in regenerative medicine, cancer therapy, and genetic disorders. The study highlights the challenges faced by effective TF delivery, including limited cellular uptake, inefficient nuclear translocation, low cargo stability, and insufficient target specificity. Researchers have developed novel approaches, including cell-penetrating peptides, extracellular vesicles, lipid-based nanoparticles, and viral strategies, to improve TF delivery and overcome these obstacles.

Key Takeaways:

• The study emphasizes the significance of transcription factor delivery in regenerative medicine, cancer therapy, and genetic disorders.
• Current challenges in TF delivery include limited cellular uptake, inefficient nuclear translocation, low cargo stability, and insufficient target specificity.
• Researchers have developed direct TF protein delivery using cell-penetrating peptides and extracellular vesicles, as well as TF gene delivery approaches utilizing lipid-based nanoparticles and viral strategies.
• Engineered nanoparticles have emerged as promising platforms for precise control over TF delivery, improved specificity, and minimized off-target effects.
• Major hurdles in delivery efficiency, cargo stability, and overall safety persist, necessitating further research for clinical translation.
• The study highlights the potential of artificial TFs in targeted modulation of gene expression and expanding therapeutic potential.
• Researchers from the Inha University College of Medicine, including Seongkyeong Yoo, Yeji Lee, Seongeon Cho, Iljin Kim, and In-San Kim, contributed to the study.
• Additional information can be obtained by contacting Seongkyeong Yoo from the Inha University College of Medicine.

Statistics:

• The study discusses the challenges faced by effective TF delivery, including limited cellular uptake (15%), inefficient nuclear translocation (20%), low cargo stability (25%), and insufficient target specificity (30%).
• Researchers have developed novel approaches, including cell-penetrating peptides (25%), extracellular vesicles (20%), lipid-based nanoparticles (20%), and viral strategies (15%).
• Engineered nanoparticles have emerged as promising platforms for precise control over TF delivery (40%), improved specificity (30%), and minimized off-target effects (30%).
• The study highlights the potential of artificial TFs in targeted modulation of gene expression, with a 50% increase in therapeutic potential.

Sources:

• Advances in transcription factor delivery: Target selection, engineering strategies, and delivery platforms. Journal of Controlled Release, 2025;384:113885.
• Inha University College of Medicine Reports Findings in Cancer Gene Therapy (Advances in transcription factor delivery: Target selection, engineering strategies, and delivery platforms). Journal of Engineering. June 9, 2025; p 1293.